Cannabis market intelligence
Decision-grade intelligence
for global cannabis.
Analyst-curated intelligence for your cannabis business. We turn primary sources, market research and proprietary datasets into structured, decision-grade intelligence.
120+countries covered1,000+companies tracked40+updated datasets420+sources monitored
125+countries covered1,050+companies tracked50+market databases450+sources monitored
Trusted by more than fifty organisations across five continents since 2018
Published intelligence
Research that moves markets.
Data-driven analysis built from the same primary-source intelligence that powers Decide.
United Kingdom · 8 Oct 2026
UK flower gets 35% stronger — while its price premium narrows
Average THC 18.4% → 24.9% since 2022 while a gram moved only £6.13 → £6.59, so THC costs 21% less per mg
Read →
Denmark · 30 Sep 2026
Denmark's medical pilot ends on a record 22,410 prescriptions
Prescriptions up 64% in 2025 for 2,465 patients, now filling 9.1 a year each — as the scheme turns permanent
Read →
Spain · 23 Sep 2026
Spain ships tonnes of cannabis abroad — its patients can reach two products
25,730 kg imported in six months, more than it exports for the first time — while just 2 of 13 preparations are registered
Read →
Netherlands · 15 Sep 2026
Dutch coffeeshops triple their range — while hash prices go the other way
25 → 78 products per shop against 27 → 36 in control towns — while hash menu prices rose 81%
Read →
Portugal · 2 Sep 2026
Portugal exports 66 tonnes in six months — as its operator base shrinks
66,305 kg shipped in H1 2026 — 83% of a record year — while licensed entities fell 49 → 43
Read →
Australia · 20 Aug 2026
Australia imports a record 81 tonnes — as its market contracts for the first time
81.1t imported and 55.3t grown at home — while units supplied fell 28.6% in H2 2025
Read →
Our analysis is cited in the press — and presented on stage
Live trackers
Six of our trackers, open to everyone and updated as the data lands.
Pick a market or a tracker to see where it stands today. Every chart below is drawn from the records we keep current in Decide, and every one of them opens the full tracker behind it.
cannamonitor.com/uk/cannamonitor.com/germany/cannamonitor.com/spain/cannamonitor.com/australia/cannamonitor.com/deal-tracker/cannamonitor.com/clinical-pipeline/Tracking six datasets
United Kingdom · NHSBSA dispensing · England
England dispensed 1.77m items of medical cannabis in 2025, and no single supplier controls the shelf any more.
Latest · Report · Sep 2026Open the UK tracker →
Items dispensed in England, 20251.77m↑ +165% on 2024England only and under-reported, so read it as a floor.↗Value has grown 24× since 2021£m at August 2026 list prices↗Two-thirds of 2025 imports reached a patientFlower, tonnes · imported (UK) vs dispensed (England)↗Curaleaf’s share fell from 61% to 25% in two years% of items · Curaleaf vs the top five operators↗Canada grows half of the flower England dispenses% of 2025 flower, by country of cultivation↗Flower THC climbed from 18.4% to 24.9%Volume-weighted THC of dispensed flower, 2022 Q1 – 2025 Q4↗Alternaleaf overtook Releaf for clinic traffic in May 2026% of tracked clinic web traffic · Sep 2025 – Aug 2026, Oct–Nov not captured↗The strongest flower took the deepest price cutsLike-for-like list-price change by THC band, Oct 2025 → Aug 2026↗
NHSBSA dispensing records (England only, a floor for the UK), Home Office import licensing, dated formulary snapshots and SimilarWeb clinic traffic. From our UK Medical Cannabis Market Report, September 2026. Read 8 Oct 2026.
Germany · BfArM · GKV · regulatory tracker
Germany imported 205 tonnes in 2025, then posted its first quarterly decline on record.
Latest · BfArM · Q1 2026Open the Germany tracker →
Flower imported into Germany, 2025205 t↑ +182% on 2024BfArM annual series, 2018–2025.↗Imports fell 17% in Q1 2026, the first decline on recordTonnes imported per quarter, Q1 2024 – Q1 2026↗Canada and Portugal supply nearly three-quartersTonnes imported in 2025, by origin↗Patients grew from ~250k to ~900k after legalisationThousands of patients · 2027–28 are our projections↗One platform draws 39% of telemedicine trafficMonthly visits, June 2026 · top six of 42 tracked↗Retail flower is down 52% in 26 months€ per gram, Cannamonitor reconciled estimate↗€205M of reimbursement is struck or gatedGKV spend 2025, €M · gold struck, teal gated, green kept↗Momentum is restrictive where the money isRegulatory momentum score, −100 to +100 · selected stories↗
BfArM quarterly import releases, GKV-Gamsi reimbursement, Cannamonitor retail price reconciliation and patient projections, SimilarWeb telemedicine traffic and our German regulatory tracker. Read 8 Oct 2026.
Spain · AEMPS · importing-country records
Spain grows medical cannabis for export, and at home only hospital pharmacies may dispense it.
Latest · Updated · Aug 2026Open the Spain tracker →
Arriving in the UK and Germany from Spain, 20258,211 kg↑ 24× the 2020 levelRecorded by the importing countries, a record year.↗Germany overtook the UK as Spain’s buyer in 2025kg recorded arriving from Spain, by destination↗Spain re-exports far more than it is authorised to growTonnes · authorised production vs exports, 2018–2024 (AEMPS / INCB)↗22,231 pharmacies, and none of them may dispense itUnder RD 903/2025 hospital pharmacy services are the whole legal channel353hospital services can22,231community pharmacies cannot↗22 cultivation authorisations across 20 entitiesAEMPS cultivation register, 22 July 2026↗Lifetime use nearly doubled to 44%; last-year use finally moved% of adults aged 15–64, OEDA 1997–2024↗Seized resin is now 30% THC, up from 12%Mean THC of analysed seizures, OEDA 2002–2021↗The decree opened a door that is barely ajarReal Decreto 903/2025, from signature to supply
- Oct 2025Decree published: hospital pharmacies only
- Jan 2026Monograph: oral solutions only, no flower
- Jan 2026Laboratory register opens
- Mar 2026Two laboratories registered
UK Home Office and BfArM records of arrivals from Spain, AEMPS / INCB production and trade, the AEMPS cultivation register, CGCOF pharmacy census, OEDA surveys and seizure analysis, and RD 903/2025. Read 8 Oct 2026.
Australia · ODC · TGA · Statistics Canada
Australia imported a record 81 tonnes in 2025, while units supplied to patients fell 28.6% in a single half.
Latest · TGA · H2 2025Open the Australia tracker →
Flower imported into Australia, 202581.1 t↑ +4.8% on 2024A record year, from ODC import records.↗Home cultivation grew 30%, far faster than importsTonnes of flower · imported vs grown in Australia↗Thailand took a quarter of imports in a single year% of 2025 flower imports, by origin↗Units supplied fell 28.6% in one halfMillions of units supplied by sponsors, 2025↗One pathway now carries 89% of the marketSpecial Access Scheme share of units supplied, H2 2021 – H2 2025↗25–30% THC is the new core of the market% of flower units by THC band↗Canada cut its Australian price 41% in a yearCA$ per kg declared into each market, H1 2025 vs H1 2026↗Alternaleaf leads Australian clinic trafficTracked monthly visits, May 2026 · top six↗
ODC import and production records, TGA sponsor supply returns (units supplied, not patients), Statistics Canada declared export values and SimilarWeb clinic traffic, May 2026. Read 8 Oct 2026.
M&A and funding tracker · 2017 to today
2026 has already logged more cannabis deals than all of 2025, with a quarter still to run.
Live · Last deal · 5 Oct 2026Open the M&A tracker →
Cannabis deals tracked, 2017 to today640+$40bn+ in disclosed valueLast deal logged 5 October 2026.↗2026 has already passed 2025’s full-year totalCannabis deals per year · 2026 to 5 October↗Up 51% on the same point last yearDeals logged 1 January – 5 October, each year↗Acquisitions are half of all dealsDeals by type · untyped records excluded↗Four markets carry most of the deal flowDeals tagged per market · one deal can carry several↗Manufacturing and cultivation change hands mostDeals tagged per supply-chain layer↗Latest deals loggedNewest first, as they land in the tracker
- Vireo Growth closes a US$60m real-estate loanUSDebt
- AYR Wellness hands its Ohio operations to its noteholdersUSAsset sale
- Griffin bids for bankrupt grow-supply distributor BFG SupplyUSAsset sale
- IM Cannabis sells its European arm, including AdjupharmIL · DEAsset sale
Every cannabis deal in our M&A and funding tracker, each linked to its source. Tags exceed deals because one deal can carry several markets or layers. Read 8 Oct 2026.
Clinical trials · 13 registries · 48 countries
Cannabinoid trial starts hit a record in 2025, yet only 16% of the pipeline is Phase III or IV.
Live · Last trial · 5 Oct 2026Open the clinical tracker →
Cannabinoid clinical trials on record2,300+13 registries · 48 countriesLast trial added 5 October 2026.↗177 trials started in 2025, a recordTrials by registered start year · 2026 so far, lighter↗Only 16% of trials are Phase III or IVTrials by phase↗Pain and neurology lead the late-phase workTrials per condition group · all vs Phase III–IV↗Industry pays for over a third of late-phase workIndustry-funded share of trials, 24 Aug 2026 analysis↗Whole-plant extracts dominate what gets testedTrials by compound class · single-class records↗429 trials are recruiting patients right nowOf the 2,300+ on record429recruiting729completed↗The US hosts more trials than the next ten countriesTrials per country, 24 Aug 2026 analysis↗
One record per trial, merged from 13 registries and deduplicated. Funder and country splits come from the 24 Aug 2026 analysis; everything else is today’s count. Read 8 Oct 2026.
Latest
InsightUK flower gets 35% stronger while its price premium narrowsM&AVireo Growth closes a US$60m real-estate loanTrialsJohns Hopkins starts a Phase II of Epidiolex in presymptomatic Sturge-Weber syndromeM&AAYR Wellness hands its Ohio operations to its noteholdersInsightDenmark’s medical pilot ends on a record 22,410 prescriptionsM&AIM Cannabis closes the sale of its European arm, including AdjupharmTrialsPleoPharma’s PP-01 cuts cannabis-withdrawal severity in a Phase 1b/2aInsightSpain ships tonnes of cannabis abroad, while its patients can reach two products
Each tracker is one slice of Decide, where the same records sit connected to every other market we cover.See how Decide connects them →
What we fix
Cannabis data is abundant. Decision-grade cannabis data is not.
Anyone can find a number. Knowing what it counts, what it leaves out and whether it agrees with the three sources that contradict it — that is the work, and that is the product.
What you are working with
What Cannamonitor gives you
✕
Numbers that don’t compareThe same market reported in four currencies, three units and two definitions — nothing reconciles.
→
✓
One schemaEvery figure standardised to one currency basis, one unit and one taxonomy, so numbers compare across jurisdictions and across time.
✕
Figures you cannot act onA growth rate with no base. A total with no definition. A record with no comparison.
→
✓
Decision-grade contextEvery figure ships with its denominator, definition, period and caveat — and the analyst read on what it actually means for the decision.
✕
AI answers you cannot auditA model synthesises contradictory public sources at speed and cites nothing you can check.
→
✓
Primary-source attributionFilings, regulator documents, customs data and court records — traced to origin, with the underlying document one click away.
✕
Data you cannot queryPDFs, screenshots and press releases. Nothing filterable, comparable or exportable.
→
✓
Structured datasets40+ datasets across 120+ countries — filter, compare, chart and export, from 420+ monitored sources.
✕
Nobody owns the judgementAggregators pass through whatever they scrape. When two sources disagree, the error reaches you.
→
✓
Analyst curationNothing enters without human review. Contradictions are reconciled and explained, never averaged away.
What you are working with
What Cannamonitor gives you
✕
Numbers that don’t compareThe same market reported in four currencies, three units and two definitions — nothing reconciles.
→
✓
One schemaEvery figure standardised to one currency basis, one unit and one taxonomy, so numbers compare across jurisdictions and across time.
✕
Figures you cannot act onA growth rate with no base. A total with no definition. A record with no comparison.
→
✓
Decision-grade contextEvery figure ships with its denominator, definition, period and caveat — and the analyst read on what it actually means for the decision.
✕
AI answers you cannot auditA model synthesises contradictory public sources at speed and cites nothing you can check.
→
✓
Primary-source attributionFilings, regulator documents, customs data and court records — traced to origin, with the underlying document one click away.
✕
Data you cannot queryPDFs, screenshots and press releases. Nothing filterable, comparable or exportable.
→
✓
Structured datasets50+ market databases across 125+ countries — filter, compare, chart and export, from 450+ monitored sources.
✕
Nobody owns the judgementAggregators pass through whatever they scrape. When two sources disagree, the error reaches you.
→
✓
Analyst curationWe decide what counts as a source, and which one wins, before any data comes in. Contradictions are reconciled and explained, never averaged away.
Free · every month
The Monthly Intelligence Brief.
A monthly review of the international cannabis markets — regulation, trade, deals and science, with the numbers behind each move. Read by 3,500+ decision-makers.
Subscribe
Unlock the insights trusted by 3,500+ cannabis leaders
Subscribers receive each issue on the day it ships. Everyone else waits a month.
Join 3,500+ cannabis leaders. No spam, unsubscribe in one click.
The platform · Decide
Twelve modules. One connected graph.
Countries and Companies are the spine. Everything else connects back to them — 50+ market databases, 640+ deals, 2,300+ trials, 10,000+ news items. 450+ monitored sources. 125+ countries. One graph.
Countries
The market-entry OS — a full relational profile per market.
- Regulation, demand, supply and competition, per jurisdiction.
- Linked to every company, deal and dataset in that market.
- Size a market or justify a pivot from one page.
| Market | Patients | Imports |
|---|---|---|
| 🇩🇪 Germany | ~900k | 205.2 t |
| 🇬🇧 UK | — | 30 t |
| 🇨🇭 Switzerland | — | 4.1 t |
Companies
The same OS, per operator — 1,000+ profiles.
- Financials, news, deals, trials and licences on one page.
- The value is the integration — everything already joined up.
- Benchmark any operator against its market and peers.
| Operator | Market | Deals |
|---|---|---|
| Vertanical | 🇩🇪 DE | 1 |
| Tilray | 🇨🇦 CA | 12 |
| Somaí | 🇵🇹 PT | 3 |
News
10,000+ items. Vetted, in-platform, past the paywalls.
- Vetted sources only — signal, not noise.
- Analyst summaries so you grasp it fast.
- Never leave the platform to read the story.
BfArMSource document attached
Regulatory
Every rule tracked by liberalisation, momentum and risk.
- Laws, policy, regulators and licences — updated as situations develop.
- Liberalisation momentum and political-risk scoring per market.
- Tied to the country and the companies it affects.
DEUKCHPLAU
Market data
40+ structured datasets. Trade flows, product directories, telemedicine, prevalence, pricing.
- Germany imports & exports, Canada flower exports, UK product directory, telemedicine across 4 markets.
- Filter, chart and export.
- Cross-cuts countries and companies.
Clinical trials
2,300+ trials. Standardised across phases, indications, sponsors.
- Find evidence by condition, substance and population.
- Readouts and status tracked over time.
- Matched to the company and product behind each trial.
THCCBD1:1Other
Science & R&D
The pipeline behind the market. Studies, readouts, investigational products.
- 71 investigational products tracked by indication, phase, mechanism and sponsor — 11 at Phase III or beyond.
- Peer-reviewed studies and readouts, linked to the trials and companies behind each asset.
- Same taxonomy as the trials database — move from evidence to product to company without leaving the graph.
Phase IISource document attached
Earnings
550+ filings. Comparable, not just collected.
- Standardised currency, units and definitions.
- Private-company signals, not only listed names.
- Tracked over time — margins and trajectory.
Q1Q2Q3Q4Q1
Content hub
30+ country briefs updated monthly. Plus insight datapacks and webinar recaps.
- 30+ country briefs, updated monthly with the latest data.
- Every insight datapack and webinar recap — with the primary data behind each figure, linked to its source.
- The full published archive, expanded and source-linked.
MonthlySource document attached
M&A & Funding
600+ deals. Consideration, multiples, investors — normalised.
- Normalised to USD and source-linked.
- Consideration split and multiples where disclosed.
- Each deal connected to buyer, target and market.
| Deal | Value |
|---|---|
| Aphria–Tilray | $3.9bn |
| Cresco–Origin | $1.1bn |
| Trulieve–Harvest | $2.1bn |
Investors
160+ investors. Who’s backing what, and at what price.
- Funds, strategics and lenders behind the deals.
- Linked to their portfolio companies.
- Spot active and emerging backers by market.
FundsStrategicsLendersOther
Analyst datapacks
120+ analyst deep-dives. The “so what”, packaged with the data behind it.
- Topic-level deep-dives built by analysts.
- The data behind every claim, attached.
- New packs added continuously.
Germany 2026Source document attached
Click any module to see what it holds
Testimonials
Trusted where the decisions get made.
Operators, investors, founders and analysts who run their calls on our data.
“The report is amazing. Congrats for being the most loved and hated person in cannabis at the same time.”
“The best reports on the market. The depth, concise insights, data visualisation — all of this make it #1.”
“Cannamonitor is the best source of international cannabis activity out there!”
“The report adds great value to the sector! Many thanks for your dedication and analysis.”
“Cannamonitor lay out a wide range of services that were exactly as requested and beyond. The professionalism in the approach was second only to the quality of commercial leads we generated as a result.”
“The quality of the information received was very specific after an in-depth analysis of the company’s strategy. Most positive was the extensive knowledge in the cannabis industry.”
“We acquired a very high depth of knowledge in a relatively small amount of time. The presentation was detailed and structured with comprehensive and attractive visuals.”
Where to start
Four ways to work with us.
Start free. Move up when the question gets bigger.
Monthly Brief
Free
One email a month. What moved in regulation, markets and science.
- ✓Monthly brief, one month after publication
- ✓Free insight articles
- ✕Same-day access to the brief
- ✕Structured datasets
- ✕Company & country profiles
Essentials
€142/year
Track the whole market. For a single professional staying current.
- ✓Brief on publication day
- ✓Full insight archive
- ✓Curated news & regulatory feed
- ✕Structured datasets & exports
- ✕Company & country profiles
Most popular
Decide
€1,420/year
The full connected graph, every module. For a professional making executive decisions.
- ✓Everything in Essentials
- ✓All 12 connected modules
- ✓40+ structured datasets, filter & export
- ✓Company, country, deal & trial profiles
- ✕Multi-seat, API and bespoke work
Enterprise & advisory
Quoted
Multi-seat access, API, bespoke monitoring and commissioned research.
- ✓Everything in Decide
- ✓Multi-seat & SSO
- ✓API and data delivery
- ✓Tailored taxonomies & alerts
- ✓Commissioned research & advisory
Monthly Brief
Free
One email a month. What moved in regulation, markets and science.
- ✓Monthly brief, one month after publication
- ✓Free insight articles
- ✕Same-day access to the brief
- ✕Structured datasets
- ✕Company & country profiles
Essentials
€142/year
Track the whole market. For a single professional staying current.
- ✓Brief on publication day
- ✓Full insight archive
- ✓Curated news & regulatory feed
- ✕Structured datasets & exports
- ✕Company & country profiles
Most popular
Decide
€1,420/year
The full connected graph, every module. For a professional making executive decisions.
- ✓Everything in Essentials
- ✓All 12 connected modules
- ✓50+ market databases, filter & export
- ✓Company, country, deal & trial profiles
- ✕Multi-seat, API and bespoke work
Enterprise & advisory
Quoted
Multi-seat access, API, bespoke monitoring and commissioned research.
- ✓Everything in Decide
- ✓Multi-seat & SSO
- ✓API and data delivery
- ✓Tailored taxonomies & alerts
- ✓Commissioned research & advisory
Track the market with the brief. Graduate to Decide when you’re ready.
Free, monthly, and read by 3,500+ people who move this market.